EXICURE, INC.
XCUR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XCUR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XCUR
Exicure, Inc. is a pre-revenue biotechnology company exploring strategic alternatives after discontinuing its historical drug development programs, with limited cash and a history of operating losses.
Key risk: Cash runway insufficient
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Exicure, Inc. is a pre-revenue biotechnology company exploring strategic alternatives after discontinuing its historical drug development programs, with limited cash and a history of operating losses.
- Cash and equivalents of $1.7M as of 2026-06-30 [sec].
- Net loss of $1.1M for the quarter ended 2026-06-30 [sec].
- Accumulated deficit of $223.0M as of December 31, 2025 [sec_mda].
- Revenue was $0.0M for the quarter ended 2026-06-30 [sec].
- The company has sold its historical biotechnology intellectual property and is exploring strategic alternatives [sec_mda].
What works
- The company has completed a sale of its historical biotechnology intellectual property and assets, generating a small one-time payment and potential future royalties [sec_mda].
- Exicure has maintained a low cash burn rate, with net loss decreasing from $9.7M in 2024 to $4.9M in 2025 [sec_mda].
What to weigh
- Cash and equivalents of $1.7M as of 2026-06-30 are insufficient to fund operations for the near term, and the company will require additional capital to continue [sec_mda].
- The company has no approved products and generated no revenue from operations in the latest quarter [sec].
- Exicure has an accumulated deficit of $223.0M as of December 31, 2025, reflecting a history of losses [sec_mda].
- The company has stated that if it is unable to raise capital, it could seek bankruptcy protection or cease operations [sec_mda].
From the filings
Quoted directly from source documents.
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Cash of $1.7M as of 2026-06-30 may not fund near-term obligations; additional capital needed [sec].
- Going concern risk — If unable to raise capital, the company could seek bankruptcy protection or cease operations [sec_mda].
- No revenue from operations — Total revenue was $0.0M in the latest quarter; no approved products [sec].
- Dependence on strategic alternatives — Future value depends on uncertain royalties or license fees from sold IP [sec_mda].
What to watch
- Ability to raise additional capital through equity offerings or other financing [sec_mda].
- Progress and outcome of exploration of strategic alternatives [sec_mda].
- Any potential royalties or license fees from the sale of historical IP [sec_mda].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run EXICURE, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available EXICURE, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
6.4 months
D/E 10.67 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$582K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 65,966 | $282K |
| geode capital management, llc | 36,913 | $158K |
| vanguard fiduciary trust co | 13,161 | $56K |
| northern trust corp | 10,686 | $45K |
| blackrock, inc. | 9,353 | $40K |
| morgan stanley | 158 | $672 |
| sbi securities co., ltd. | 43 | $183 |
| osaic holdings, inc. | 29 | $123 |
| prestige wealth management group llc | 20 | $86 |
| harbour investments, inc. | 17 | $72 |
Showing top 10 of 14 institutional holders of EXICURE, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 1.9%
- Days to cover
- 2.5
- Shares short
- 57,656
- Daily short volume (May 7, 2026)
- 58.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XCUR short interestGovernance
Frequently asked questions
What is the AI investment thesis for EXICURE, INC.?
Exicure, Inc. is a pre-revenue biotechnology company exploring strategic alternatives after discontinuing its historical drug development programs, with limited cash and a history of operating losses.
Who is the CEO of EXICURE, INC.?
Mr. Jungsoo Kim is the chief executive officer of EXICURE, INC. (XCUR).
Where is EXICURE, INC. headquartered?
EXICURE, INC. (XCUR) is headquartered in Redwood City, CA, United States.
What therapeutic areas does EXICURE, INC. focus on?
EXICURE, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.